According to the new market research report "Allergy Diagnostics Market by Product Service (Consumables, Instruments (Immunoassay Analyzer, ELISA Analyzer, Luminometer), Service), Allergen (Food, Inhaled, Drug), Test Type (In Vivo, In Vitro), End User (Diagnostic Laboratories) - Global Forecast to 2026", The global allergy diagnostics market is projected to reach USD 8.2 billion by 2026 from USD 4.8 billion in 2021, at a CAGR of 11.1% from 2021 to 2026.
Browse in-depth TOC on "Allergy Diagnostics Industry"
358 - Tables
46 - Figures
301 – Pages
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701
The growth of this market is driven by the high incidence of allergic diseases and associated heavy economical burden, rising environmental pollution levels, increasing funds by organizations in allergy diagnostics, and the increasing access to healthcare insurance.
“Consumables are expected to hold the largest share of the allergy diagnostics market, by product service in 2021.”
Based on product service, the allergy diagnostics market is segmented into consumables, instruments, and services. In 2020, the consumables segment accounted for the largest share of the allergy diagnostics market. The large share of the consumables segment can be attributed to the increasing cases of allergies and the need for rapid tests to diagnose allergic conditions. The consumables segment is also expected to witness significant growth during the forecast period.
“In vivo tests are expected to hold the largest share of the allergy diagnostics market, by test type in 2021.”
Based on test type, the allergy diagnostics market is segmented into in vivo tests and in vitro tests. In 2020, the in vivo tests segment accounted for the largest share of the allergy diagnostics market. The growth of this segment is mainly driven by the increasing adoption of various in vivo tests, such as skin prick tests. These tests are dependable, safe, convenient, and cost-effective, as compared to in vitro tests.
Request Free Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=232871701
“Inhaled allergens are expected to hold the largest share of the allergy diagnostics market, by allergen in 2021.”
Based on allergens, the allergy diagnostics market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. In 2020, the inhaled allergens segment accounted for the largest share of the allergy diagnostics market due to the increasing environmental pollution and rising pollen coupled with other factors such as fungus, mold, and dust.
“Diagnostic laboratories are expected to hold the largest share of the allergy diagnostics market, by end user in 2021.”
Based on end user, the allergy diagnostics market is segmented into diagnostic laboratories, hospital-based laboratories, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the market. The large share of the segment can be primarily attributed to the preference for proper diagnosis from a specialist, rising awareness regarding the management of allergic diseases, and the availability of funds for the operation of independent diagnostic laboratories.
“North America commanded the largest share of the allergy diagnostics industry in 2021.”
Based on region, the allergy diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. In 2020, North America commanded the largest share of the allergy diagnostics market. The large share of North America can be attributed to the rising incidence of allergies, favorable reimbursement scenarios for allergy diagnosis, and the availability of supportive initiatives by associations.
The major players operating in this market are Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).
Key Developments:
- In 2021, Hitachi Chemical Diagnostics, Inc. has been renamed Minaris Medical America, Inc. By uniting the medical business group companies under the name of Minaris Medical, Hitachi aims to strengthen its global presence and expand business operations in the field of in-vitro diagnostics. The companies are a part of Showa Denko Materials Co., Ltd. (renamed from Hitachi Chemical Co., Ltd. on Oct 1, 2020).
- In 2021, PerkinElmer Inc. entered into an agreement with Immunodiagnostic Systems Holdings PLC to acquire the later. The acquisition will enable PerkinElmer Inc. to strengthen its position in the ImmunoDiagnostics (IDS) market. IDS would be incorporated under EUROIMMUN Medizinische LABORDIAGNOSTIKA AG, a company offering allergy products and solutions.
- In 2020, NEOGEN Corporation launched Reveal 3-D for Gluten
- In 2019, Romer Labs Division Holding GmbH opened its APAC Solutions Centre in Singapore. The APAC Solutions Centre features new facilities for food allergen testing.
- In 2018, Omega Diagnostics Group PLC and Immunodiagnostic Systems (IDS) entered into a supply agreement through which Immunodiagnostic Systems (IDS) is the official distributor of allergy tests offered by Omega Diagnostics Group PLC.
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=232871701
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/allergy-diagnostics-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/allergy-diagnostics.asp
